All Oncology News

Limited knowledge of long-term irAEs points to the need for more concentrated research regarding optimal postimmunotherapy toxicity management.

The top 5 OncLive TV videos of the week cover insights in chronic lymphocytic leukemia, ovarian cancer, lung cancer, breast cancer, and prostate cancer.

The FDA has cleared nivolumab/AVD for classical Hodgkin lymphoma, accepted a bezuclastinib NDA for review in nonadvanced systemic mastocytosis, and more.

Pathologists play a key role in lung cancer care, from biomarker testing to tissue triage.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Nadofaragene firadenovec has been added to the NCCN guidelines in BCG-unresponsive papillary NMIBC without CIS.

The FDA has approved nivolumab plus AVD for adult and pediatric patients with previously untreated, stage III or IV classical Hodgkin lymphoma.

CNS-penetrant TKIs are reshaping brain metastases care in lung cancer, shifting sequencing decisions between systemic and local therapy.

Jorge Cortes, MD, discusses available TKIs and how to navigate optimal treatment selection for patients with chronic myeloid leukemia.

Tucatinib and trastuzumab, plus capecitabine, may improve symptoms and extend survival in some breast cancer patients with leptomeningeal metastasis.

Sarah Sammons, MD, discusses how pumitamig’s dual-protein targets position it as a unique agent within the TNBC treatment arena.

PSA decline or control was not found to be concordant with PSMA tumor volume changes among enzalutamide-treated patients with BCR prostate cancer.

Ulka Vaishampayan, MD, FASCO, discusses different novel therapies in development for renal cell carcinoma.

The phase 3 TALAPRO-3 study evaluating talazoparib plus enzalutamide HRR gene–mutated mCSPC met its primary end point.

A new gene-editing approach developed at UCSF treated leukemia, multiple myeloma, and sarcoma in mice by precisely reprogramming immune cells with no external manufacturing required.

Nicole Lamanna, MD, discusses both CLL 17 and FLAIR studies and their significance for chronic lymphocytic leukemia.

Lutetium Lu 177 vipivotide tetraxetan was active after treatment with sipuleucel-T in real-world mCRPC.

However, a trend towards OS benefit was observed when treatment with cabozantinib was deferred until after disease progression vs administered upfront.

First-line sacituzumab govitecan plus pembrolizumab generated efficacy and safety improvements vs chemotherapy plus pembrolizumab in PD-L1–positive mTNBC.

David B. Solit, MD, discusses ongoing efforts to develop ADCs and other novel treatment approaches beyond EV plus pembrolizumab in urothelial cancer.

Distinct tumor-immune ecologies helpful for distinguishing stable and progressive disease in NSCLC have been identified by Moffitt Cancer Center.

The regulatory agency green lit the use of MyChoice CDx as a companion diagnostic for niraparib in advanced ovarian cancer

First-line ficerafusp alfa at 2000 mg every 2 weeks plus pembrolizumab was deemed safe and effective in recurrent or metastatic HPV-negative HNSCC.

The NCCN Guidelines endorse frontline sacituzumab govitecan alone for PD-L1–negative mTNBC and in combination with pembrolizumab for PD-L1–positive mTNBC.

Mayo Clinic researchers have developed a promising new way to deliver treatment directly to cholangiocarcinoma.

Patients with HLA-A*02–negative, HER2-positive early breast cancer experienced a recurrence rate of less than 1% when treated with GLSI-100.GLSI-100

The NCCN guidelines in bladder cancer now include nogapendekin alfa inbakicept plus BCG for BCG-unresponsive NMIBC with papillary-only disease.

Nicole Lamanna, MD, discusses the implications of the FDA approval of frontline acalabrutinib plus venetoclax in CLL.

Retrospective data showed longer durations of bridging therapy with a BTK inhibitor improved CAR T-cell therapy response in relapsed/refractory DLBCL.

Acalabrutinib/lenalidomide in combination with rituximab or obinutuzumab generated uMRD6 CRs in previously untreated mantle cell lymphoma.